Management

Ronald W. Barrett, Ph.D.
Chief Executive Officer and Director

William J. Rieflin
President

William G. Harris
Senior Vice President of Finance and Chief Financial Officer

Vincent J. Angotti
Senior Vice President and Chief Commercialization Officer

Kenneth C. Cundy, Ph.D.
Senior Vice President of Preclinical Development

Mark A. Gallop, Ph.D.
Senior Vice President of Research

David R. Savello, Ph.D.
Senior Vice President of Development

David A. Stamler, M.D.
Senior Vice President and Chief Medical Officer

---

Ronald W. Barrett, Ph.D.
Chief Executive Officer and Director

Ronald W. Barrett is one of our founders and has served as our chief executive officer since 2001. He served as our chief scientific officer from 1999 to 2001. Dr. Barrett has been a director since August 1999. From 1989 to 1999, he held various positions at Affymax Research Institute (acquired by Glaxo Welcome plc, now known as GSK, in 1995), the most recent of which was senior vice president of research. Prior to Affymax Research Institute, Dr. Barrett was a molecular pharmacologist in the Neuroscience Group at Abbott Laboratories from 1986 to 1989. Dr. Barrett received a B.S. from Bucknell University and a Ph.D. in pharmacology from Rutgers University.

William J. Rieflin
President

William J. Rieflin has been our president since 2004. From 1996 to 2004, he held various positions with Tularik Inc., the most recent of which was executive vice president, administration, chief financial officer, general counsel and secretary. Amgen Inc. acquired Tularik in 2004. Mr. Rieflin received a B.S. from Cornell University, an M.B.A. from the University of Chicago Graduate School of Business and a J.D. from Stanford Law School.

William G. Harris
Senior Vice President of Finance and Chief Financial Officer

William G. Harris has been our senior vice president of finance and chief financial officer since 2001. From 1996 to 2001, he held several positions with Coulter Pharmaceutical, Inc., the most recent of which was senior vice president and chief financial officer. Corixa Corp. acquired Coulter Pharmaceutical in 2000. Prior to Coulter Pharmaceutical, from 1990 to 1996, Mr. Harris held several positions at Gilead Sciences, Inc., most recently as director of finance. Mr. Harris received a B.A. from the University of California, San Diego and an M.B.A. from Santa Clara University, Leavey School of Business and Administration.

Vincent J. Angotti
Senior Vice President and Chief Commercialization Officer

Vincent J. Angotti has been our senior vice president and chief commercialization officer since May 2008. From 2001 to 2008, he held several positions with Reliant Pharmaceuticals, Inc., the most recent of which was senior vice president of sales and marketing. GlaxoSmithKline acquired Reliant Pharmaceuticals in 2008. Prior to Reliant Pharmaceuticals, from 1991 to 2001, Mr. Angotti held several positions at Novartis Pharmaceuticals Corporation, most recently as executive director, field operations. Mr. Angotti received a B.S. from Cornell University and an M.B.A. from Columbia University.

Kenneth C. Cundy, Ph.D.
Senior Vice President of Preclinical Development

Kenneth C. Cundy has been our senior vice president of preclinical development since 2004. He was previously our vice president of biopharmaceutics from 2000 to 2004. From 1992 to 2000, he was senior director of biopharmaceutics at Gilead Sciences, Inc. Prior to Gilead Sciences, from 1988 to 1992, Dr. Cundy was principal research investigator at Sterling Drug, a pharmaceutical division of Eastman Kodak Company. He received a B.S. from the University of Manchester and a Ph.D. in pharmaceutical sciences from the University of Kentucky.

Mark A. Gallop, Ph.D.
Senior Vice President of Research

Mark A. Gallop is one of our founders and has been our senior vice president of research since 2004. He was previously our vice president of chemistry since 1999. From 1990 to 1999, Dr. Gallop held several positions at Affymax Research Institute, the most recent of which was senior director of combinatorial chemistry. Dr. Gallop received a B.Sc. from the University of Auckland and a Ph.D. in inorganic chemistry from the University of Cambridge.

David R. Savello, Ph.D.
Senior Vice President of Development

David R. Savello has been our senior vice president of development since February 2007. He was previously responsible for our regulatory affairs, quality and project management from 2005 to 2007. From 1999 to 2005, Dr. Savello was executive vice president and chief scientific officer for the Pharmaceutical Technology and Services Sector of Cardinal Health, Inc. Prior to joining Cardinal Health, from 1997 to 1999, he was senior vice president for drug development at Guilford Pharmaceuticals Inc. From 1985 to 1997, Dr. Savello held several positions at Glaxo and Glaxo Wellcome including both vice president of drug development and vice president of regulatory affairs and compliance. Prior to that, he held R&D management and executive management positions at Boehringer Ingelheim GmbH and 3M Company. Dr. Savello received his B.S. degree from the Massachusetts College of Pharmacy and both an M.S. and a Ph.D. in pharmaceutics from the University of Maryland School of Pharmacy.

David A. Stamler, M.D.
Senior Vice President and Chief Medical Officer

David A. Stamler, M.D., has been our senior vice president and chief medical officer since July 2008. From 2005 to 2008, Dr. Stamler was chief scientific officer and head of drug development for Prestwick Pharmaceuticals, Inc. where he led clinical and pre-clinical development activities for a portfolio of CNS compounds. Prior to Prestwick, from 1997 to 2005, Dr. Stamler held several positions with Fujisawa Pharmaceutical Company, the most recent of which was senior global project leader for CNS Diseases and vice president of research and development, Medical Sciences for Fujisawa's U.S. subsidiary, Fujisawa Healthcare, Inc. From 1993 to 1997, Dr. Stamler held several positions with Abbott Laboratories, the most recent of which was director of clinical research, Pharmaceutical Products for the International Division. Dr. Stamler received B.A. and M.D. degrees from the University of Chicago. He completed his residency in internal medicine at Temple University Hospital, as well as fellowships in infectious diseases and clinical microbiology at the University of Pennsylvania. He is board certified in internal medicine. Dr. Stamler is a founding member of the American Society of Experimental NeuroTherapeutics (ASENT) and a member of the American Academy of Neurology and the American College of Physicians. He has authored publications in peer-reviewed scientific journals for CNS, gastrointestinal, respiratory and inflammatory diseases.